Skip to main content
BMJ Clinical Evidence logoLink to BMJ Clinical Evidence
. 2009 Nov 12;2009:0506.

Tinnitus

Julian Savage 1,#, Stephanie Cook 2,#, Angus Waddell 3,#
PMCID: PMC2907768  PMID: 21726476

Abstract

Introduction

Up to 18% of people in industrialised societies are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their daily life. Tinnitus can be associated with hearing loss, acoustic neuromas, drug toxicity, ear diseases, and depression. Tinnitus can last for many years, and can interfere with sleep and concentration.

Methods and outcomes

We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for chronic tinnitus? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results

We found 27 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions

In this systematic review, we present information relating to the effectiveness and safety of the following interventions: acamprosate; acupuncture; antidepressant drugs; benzodiazepines; carbamazepine; cinnarizine; electromagnetic stimulation; ginkgo biloba; hearing aids; hypnosis; psychotherapy; tinnitus-masking devices; and tinnitus retraining therapy.

Key Points

Up to 18% of people in industrialised societies are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their daily life.

  • Tinnitus can be associated with hearing loss, acoustic neuromas, drug toxicity, ear diseases, or depression.

  • Tinnitus can last for many years, and can interfere with sleep and concentration.

There is insufficient evidence to show that antidepressant drugs improve tinnitus symptoms.

  • Antidepressant drugs can improve depression in people with tinnitus.

  • Tricyclic antidepressants (TCAs) are associated with adverse effects such as dry mouth, blurred vision, and constipation.

CBT may be ineffective at reducing tinnitus loudness, but it may improve quality of life in people with tinnitus.

We don't know whether benzodiazepines, acupuncture, hypnosis, electromagnetic stimulation, hearing aids, tinnitus-masking devices, tinnitus retraining therapy, cinnarizine, ginkgo biloba, or acamprosate are effective in people with tinnitus, because very few studies have been carried out.

Carbamazepine may be no more effective than placebo at improving symptoms of tinnitus, and is associated with adverse effects such as dizziness, nausea, and headache.

About this condition

Definition

Tinnitus is the perception of sound in the ear or head that does not arise from the external environment, from within the body (e.g., vascular sounds), or from auditory hallucinations related to mental illness. This review is concerned with tinnitus for which tinnitus is the only, or the predominant, symptom in an affected person.

Incidence/ Prevalence

Up to 18% of the general population in industrialised countries are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their ability to lead a normal life.

Aetiology/ Risk factors

Tinnitus can occur as an isolated idiopathic symptom, or in association with any type of hearing loss. Tinnitus can be a particular feature of presbycusis (age-related hearing loss), noise-induced hearing loss, Menière's disease (see review on Menière's disease), or the presence of an acoustic neuroma. In people with toxicity from aspirin or quinine, tinnitus can occur with hearing thresholds remaining normal. Tinnitus is also associated with depression, although it can be unclear whether the tinnitus is a manifestation of the depressive illness or a factor contributing to its development. Studies involving people with tinnitus caused by Menière's disease, acoustic neuroma, chronic otitis media, head injury, barotraumas, or other clear pathology have been excluded from this review. This review is principally concerned with idiopathic tinnitus with or without degenerative sensorineural hearing loss.

Prognosis

Tinnitus can have an insidious onset, with a long delay before clinical presentation. It can persist for many years or decades, particularly when associated with a sensorineural hearing loss. Tinnitus can cause disruption of sleep patterns, an inability to concentrate, and depression.

Aims of intervention

To reduce the loudness and intrusiveness of the tinnitus, and to reduce its impact on daily life, with minimum adverse effects of treatment.

Outcomes

Resolution of tinnitus; improvement in tinnitus (includes tinnitus loudness [assessed by a visual analogue scale or symptom scores]); impact of tinnitus on quality of life, as measured by estimates of interference with activities of daily life or with emotional state; and adverse effects of treatment.

Methods

Clinical Evidence search and appraisal May 2009. The following databases were used to identify studies for this systematic review: Medline 1966 to May 2009, Embase 1980 to May 2009, and The Cochrane Database of Systematic Reviews, Issue 2, 2009 (1966 to date of issue). An additional search within the Cochrane Library was carried out for the Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA). We also searched for retractions of studies included in the review. Abstracts of the studies retrieved from the initial search were assessed by an information specialist. Selected studies were then sent to the contributor for additional assessment, using pre-determined criteria to identify relevant studies. Study design criteria for inclusion in this review were: published systematic reviews of RCTs and RCTs in any language, at least single blinded, and containing more than 20 individuals of whom more than 80% were followed up. There was no minimum length of follow-up required to include studies. We excluded all studies described as "open", "open label", or not blinded unless blinding was impossible. We included systematic reviews of RCTs and RCTs where harms of an included intervention were studied applying the same study design criteria for inclusion as for benefits. In addition, we use a regular surveillance protocol to capture harms alerts from organisations such as the FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA), which are added to the reviews as required. To aid readability of the numerical data in our reviews, we round many percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table). The categorisation of the quality of the evidence (high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes in our defined populations of interest. These categorisations are not necessarily a reflection of the overall methodological quality of any individual study, because the Clinical Evidence population and outcome of choice may represent only a small subset of the total outcomes reported, and population included, in any individual trial. For further details of how we perform the GRADE evaluation and the scoring system we use, please see our website (www.clinicalevidence.com).

Table.

GRADE Evaluation of interventions for Tinnitus.

Important outcomes Impact of tinnitus on quality of life, Improvement in tinnitus, Resolution of tinnitus
Studies (Participants) Outcome Comparison Type of evidence Quality Consistency Directness Effect size GRADE Comment
What are the effects of treatments for chronic tinnitus?
1 (50) Improvement in tinnitus Acamprosate versus placebo 4 –2 0 0 0 Low Quality points deducted for sparse data and no intention-to-treat analysis
3 (122) Improvement in tinnitus Acupuncture versus sham acupuncture 4 –2 –1 0 0 Very low Quality points deducted for sparse data and incomplete reporting of results. Consistency point deducted for conflicting results
1 (54) Impact of tinnitus on quality of life Acupuncture versus sham acupuncture 4 –2 0 0 0 Low Quality points deducted for sparse data and incomplete reporting of results
4 (405) Improvement in tinnitus TCAs versus placebo 4 –1 0 0 0 Moderate Quality point deducted for incomplete reporting of results
1 (117) Impact of tinnitus on quality of life TCAs versus placebo 4 –2 0 0 0 Low Quality points deducted for sparse data and for incomplete reporting of results
2 (196) Improvement in tinnitus SSRIs versus placebo 4 –1 0 –1 0 Low Quality point deducted for sparse data. Directness point deducted for inclusion of a co-intervention in one RCT (oxazepam)
1 (76) Impact of tinnitus on quality of life SSRIs versus placebo 4 –2 0 –1 0 Very low Quality points deducted for sparse data and for RCT being underpowered to detect a clinically meaningful difference between groups. Directness point deducted for inclusion of a co-intervention (oxazepam)
1 (40) Improvement in tinnitus Benzodiazepines versus placebo 4 –3 0 0 0 Very low Quality points deducted for sparse data, incomplete reporting of results, and flaws with blinding
1 (30) Improvement in tinnitus Cinnarizine versus placebo 4 –3 0 0 0 Very low Quality points deducted for sparse data, incomplete reporting of results, and uncertain follow-up
2 (78) Improvement in tinnitus Electromagnetic stimulation versus placebo 4 –3 –1 0 0 Very low Quality points deducted for sparse data, incomplete reporting of results, and other methodological flaws. Consistency point deducted for conflicting results
1 (66) Improvement in tinnitus Ginkgo biloba versus placebo 4 –1 0 0 0 Moderate Quality point deducted for sparse data
1 (39) Improvement in tinnitus Hearing aids versus waiting list control 4 –2 0 0 0 Low Quality points deducted for sparse data and incomplete reporting of results
1 (92) Improvement in tinnitus Hypnosis versus counselling 4 –2 0 –1 0 Very low Quality points deducted for sparse data and incomplete reporting of results. Directness point deducted for inclusion of only those who were suggestible to hypnosis
4 (171) Improvement in tinnitus CBT versus placebo 4 –2 0 0 0 Low Quality points deducted for sparse data, and for methodological flaws of one review
at least 4 (at least 152) Impact of tinnitus on quality of life CBT versus placebo 4 –2 0 0 0 Low Quality points deducted for sparse data, and for methodological flaws of one review
1 (42) Improvement in tinnitus Tinnitus-masking devices versus placebo 4 –3 0 0 0 Very low Quality points deducted for sparse data, no blinding, incomplete reporting of results, and other methodological flaws (reporting of post-crossover results)
1 (48) Improvement in tinnitus Carbamazepine versus placebo 4 –2 0 0 0 Low Quality points deducted for sparse data and incomplete reporting of results

We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasi-randomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.

Glossary

Low-quality evidence

Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Masking device

A small device similar to a behind-the-ear hearing aid that produces a broad frequency noise. It is thought to hide the noise of the tinnitus.

Menière's disease

A condition characterised by episodic vertigo, tinnitus, and sensorineural hearing loss.

Moderate-quality evidence

Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Presbycusis

Age-related hearing loss.

Tinnitus Handicap Inventory

A questionnaire assessing the impact of tinnitus on the subject's quality of life.

Tinnitus retraining therapy

A combination of cognitive behavioural therapy and tinnitus masking, highly tailored to individual people.

Very low-quality evidence

Any estimate of effect is very uncertain.

Disclaimer

The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices. Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research we strongly recommend that readers' independently verify specified treatments and drugs including manufacturers' guidance. Also, the categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately it is the readers' responsibility to make their own professional judgements, so to appropriately advise and treat their patients.To the fullest extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, incidental or consequential, resulting from the application of the information in this publication.

Contributor Information

Julian Savage, Southmead Hospital, Bristol, UK.

Stephanie Cook, April Cottage, Buxted, East Sussex, UK.

Angus Waddell, Great Western Hospital, Swindon, UK.

References

  • 1.Coles RR. Epidemiology of tinnitus: (1) prevalence. J Laryngol Otol 1984;9(suppl):7–15. [DOI] [PubMed] [Google Scholar]
  • 2.Sullivan MD, Katon W, Dobie R, et al. Disabling tinnitus: association with affective disorder. Gen Hosp Psychiatry 1988;10:285–291. [DOI] [PubMed] [Google Scholar]
  • 3.Zoger S, Svedlund J, Holgers KM. Psychiatric disorders in tinnitus patients without severe hearing impairment: 24 month follow-up of patients at an audiological clinic. Audiology 2001;40:133–140. [DOI] [PubMed] [Google Scholar]
  • 4.Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: double-blind study. Rev Bras Otorhinolaringol 2005;71:618–623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Park J, White AR, Ernst E. Efficacy of acupuncture as a treatment for tinnitus: a systematic review. Arch Otolaryngol Head Neck Surg 2000;126:489–492. Search date 1998; primary sources Medline, Cochrane Controlled Trials Register, Embase, and Ciscom. [DOI] [PubMed] [Google Scholar]
  • 6.Axelsson A, Andersson S, Gu LD. Acupuncture in the management of tinnitus: a placebo-controlled study. Audiology 1994;33:351–360. [DOI] [PubMed] [Google Scholar]
  • 7.Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by biofeedback, acupuncture and drug therapy. Ear Nose Throat J 1991;70:284–289. [PubMed] [Google Scholar]
  • 8.Furugard S, Hedin PJ, Eggertz A, et al. Acupuncture worth trying in severe tinnitus. Lakartidningen 1998;95:1922–1928. [In Swedish] [PubMed] [Google Scholar]
  • 9.Marks NJ, Emery P, Onisiphorou C. A controlled trial of acupuncture in tinnitus. J Laryngol Otol 1984;98:1103–1109. [DOI] [PubMed] [Google Scholar]
  • 10.Hansen PE, Hansen JH, Bentzen O. Acupuncture therapy of chronic unilateral tinnitus. A double-blind cross-over study. Ugeskr Laeger 1981;143:2888–2890. [In Danish] [PubMed] [Google Scholar]
  • 11.Vilholm OJ, Moller K, Jorgensen K. Effect of traditional Chinese acupuncture on severe tinnitus: a double-blind, placebo-controlled, clinical investigation with open therapeutic control. Br J Audiol 1998;32:197–204. [DOI] [PubMed] [Google Scholar]
  • 12.Baldo P, Doree C, Lazzarini R, et al. Antidepressants for patients with tinnitus. In: The Cochrane Library, Issue 2, 2009. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006. 17054188 [Google Scholar]
  • 13.Bayar N, Boke B, Turan E, et al. Efficacy of amitriptyline in the treatment of subjective tinnitus. J Otolaryngol 2001;30:300–303. [DOI] [PubMed] [Google Scholar]
  • 14.Mihail RC, Crowley JM, Walden BE, et al. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otolo Rhinol Laryngol 1988;97:120–123. [DOI] [PubMed] [Google Scholar]
  • 15.Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by amitryptiline hydrochloride/biofeedback. Int Tinnitus J 1995;1:54–60. [PubMed] [Google Scholar]
  • 16.Sullivan M, Katon W, Russo J, et al. A randomised trial of nortriptyline for severe chronic tinnitus. Arch Intern Med 1993;153:2251–2259. [PubMed] [Google Scholar]
  • 17.Robinson SK, Viirre ES, Bailey KA, et al. Randomised placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005;67:981–988. [DOI] [PubMed] [Google Scholar]
  • 18.Zoger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering - a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:32–39. [DOI] [PubMed] [Google Scholar]
  • 19.Schilter B, Jager B, Heerman R, et al. Pharmacological and psychological treatment options in chronic subjective tinnitus: a meta-analysis of effective treatments. HNO 2000;48:589–597. Search date 1995; primary sources Medline, Psyindex, Psychlit, and hand searches including German, English, and French language papers. [In German] 10994170 [Google Scholar]
  • 20.Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993;119:842–845. [DOI] [PubMed] [Google Scholar]
  • 21.Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202–1211. Search date 1998; primary sources Medline and hand searches. [DOI] [PubMed] [Google Scholar]
  • 22.Roland NJ, Hughes JB, Daley MB, et al. Electromagnetic stimulation as a treatment of tinnitus: a pilot study. Clin Otolaryngol 1993;18:278–281. [DOI] [PubMed] [Google Scholar]
  • 23.Dobie RA, Hoberg KE, Rees TS. Electrical tinnitus suppression: a double-blind crossover study. Otolaryngol Head Neck Surg 1986;95:319–333. [DOI] [PubMed] [Google Scholar]
  • 24.Hilton M, Stuart E. Ginkgo biloba for tinnitus. In: The Cochrane Library, Issue 2, 2009. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006. [Google Scholar]
  • 25.Morgenstern C, Biermann E. Long-term treatment of tinnitus with the special gingko extract, Egb 761. Fortschr Med 1997;115:57–58. [In German] [Google Scholar]
  • 26.Drew S, Davies E. Effectiveness of ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ 2001;322:73–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci 2004;29:226–231. [DOI] [PubMed] [Google Scholar]
  • 28.Melin L, Scott B, Lindberg P, et al. Hearing aids and tinnitus – an experimental group study. Br J Audiol 1987;21:91–97. [DOI] [PubMed] [Google Scholar]
  • 29.Mason JD, Rogerson DR, Butler JD. Client centred hypnotherapy in the management of tinnitus — is it better than counselling? J Laryngol Otol 1996;110:117–120. [DOI] [PubMed] [Google Scholar]
  • 30.Martinez Devesa P, Waddell A, Perera R, et al. Cognitive behavioural therapy for tinnitus. In: The Cochrane Library, Issue 2, 2009. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006. 17253549 [Google Scholar]
  • 31.Andersson G, Lyttkens L. A meta-analytic review of psychological treatments for tinnitus. Br J Audiol 1999;33:201–210. Search date 1998; primary sources Medline and psychological abstracts. [DOI] [PubMed] [Google Scholar]
  • 32.Stephens SDG, Corcoran AL. A controlled study of tinnitus masking. Br J Audiol 1985;19:159–167. [DOI] [PubMed] [Google Scholar]
  • 33.Erlandsson S, Ringdahl A, Hutchins T, et al. Treatment of tinnitus: a controlled comparison of masking and placebo. Br J Audiol 1987;21:37–44. [DOI] [PubMed] [Google Scholar]
  • 34.Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec 1985;47:262–266. [DOI] [PubMed] [Google Scholar]
BMJ Clin Evid. 2009 Nov 12;2009:0506.

Acamprosate

Summary

We don't know whether acamprosate is effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Acamprosate versus placebo:

We found one RCT.

Improvement in tinnitus

Acamprosate compared with placebo Acamprosate may reduce the severity of tinnitus after 3 months, although the improvement may not be clinically important (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms of tinnitus

RCT
50 people with subjective tinnitus Proportion of people with improvement in tinnitus (measured on a 10-point tinnitus score [scale of 0–10; increasing score is associated with increasing disturbance from tinnitus]) 3 months
87% with acamprosate 333 mg three times daily
44% with placebo
Absolute numbers not reported

P = 0.0004
It is unclear whether the difference in scores reflects a clinically important improvement in tinnitus
People who dropped out of the RCT were not included in the data analysis, which would have affected the results
Effect size not calculated acamprosate

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
50 people with subjective tinnitus Proportion of people with an adverse effect 3 months
12% with acamprosate 333 mg three times daily
20% with placebo
Absolute numbers not reported

P = 0.35
People who dropped out of the RCT were not included in the data analysis, which would have affected the results
Not significant

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Acupuncture

Summary

We don't know whether acupuncture is effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Acupuncture versus sham acupuncture:

We found one systematic review (search date 1998; 6 studies; 185 people). The review included one quasi-randomised RCT, two open RCTs, two crossover RCTs, and one blinded RCT. All studies were small and brief.

Improvement in tinnitus

Acupuncture compared with sham acupuncture We don't know whether acupuncture is more effective at reducing the severity of tinnitus at 3 weeks to 2 months (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus loudness

RCT
54 people
In review
Change in mean tinnitus loudness score (assessed using a pooled visual analogue score; change from baseline)
From 78.5 to 74.1 with acupuncture (25 sessions of 30 minutes over 2 months)
From 76.5 to 77.5 with sham acupuncture (superficial penetration at random, non-acupuncture points)

Reported as not significant
P value not reported
Not significant
Overall symptoms of tinnitus

RCT
Crossover design
14 people
In review
Proportion of people with subjective improvement in tinnitus (measured by verbal description, tinnitus matching, and visual analogue scale for tinnitus loudness) after one session of treatment
5/14 (36%) with acupuncture
0/14 (0%) with sham acupuncture

P <0.05
Effect size not calculated acupuncture

RCT
Crossover design
20 people
In review
Improvement in subjective tinnitus severity (measured using a pooled visual analogue score) 3 weeks
with acupuncture
with placebo
Absolute results not reported

P = 0.22
Not significant

RCT
54 people
In review
Change in mean tinnitus awareness (assessed using a pooled visual analogue score; change from baseline)
From 69.2 to 64.5 with acupuncture (25 sessions of 30 minutes over 2 months)
From 65.1 to 66.5 with sham acupuncture (superficial penetration at random, non-acupuncture points)

Reported as not significant
P value not reported
Not significant

Impact of tinnitus on quality of life

Acupuncture compared with sham acupuncture We don't know whether acupuncture is more effective at reducing annoyance as a result of tinnitus (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Annoyance

RCT
54 people
In review
Change in mean tinnitus annoyance score (assessed using a pooled visual analogue score; change from baseline)
From 64.5 to 62.0 with acupuncture (25 sessions of 30 minutes over 2 months)
From 67.1 to 67.0 with sham acupuncture (superficial penetration at random, non-acupuncture points)

Reported as not significant
P value not reported
Not significant

No data from the following reference on this outcome.

Resolution of tinnitus

No data from the following reference on this outcome.

Adverse effects

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Antidepressant drugs

Summary

There is insufficient evidence to show that antidepressant drugs improve tinnitus symptoms.

Antidepressant drugs can improve depression in people with tinnitus.

TCAs are associated with adverse effects such as dry mouth, blurred vision, and constipation.

Benefits and harms

TCAs versus placebo:

We found one systematic review (search date 2006; 4 RCTs; 405 people) comparing TCAs versus placebo. No meta-analysis was performed.

Improvement in tinnitus

Tricyclic antidepressants (TCAs) compared with placebo TCAs seem no more effective at reducing the severity of tinnitus after 6 weeks (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus loudness

RCT
Crossover design
26 people
In review
Improvement in subjective tinnitus loudness (mean subjective rating on a scale of 1–7) 6 weeks
4.3 with trimipramine (150 mg/day for 6 weeks)
4.0 with placebo

Reported as not significant
P value not reported
Not significant

RCT
4-armed trial
225 people
In review
Proportion of people with improvement in subjective tinnitus loudness at rest
28% with amitriptyline (10 mg three times a day for 10 weeks)
5% with placebo
Absolute numbers not reported

P <0.011 (as reported in RCT)
The review reported that results were presented as percentages, and further analysis is not possible
Effect size not calculated amitriptyline
Overall symptoms of tinnitus

RCT
37 people with no history of depression
In review
Proportion of people with a decrease in subjective tinnitus 6 weeks
19/20 (95%) with amitriptyline (50 mg/night for 1 week followed by 100 mg/night for 5 weeks)
2/17 (12%) with placebo

Statistical analysis between groups not reported

RCT
Crossover design
26 people
In review
Proportion of people with worsening of tinnitus (mean subjective rating on a scale of 1–7) 6 weeks
7/19 (37%) with trimipramine (150 mg/day for 6 weeks)
4/19 (21%) with placebo

Significance not assessed

RCT
117 people; results are reported for the 92 people who completed the follow-up period
In review
Proportion of people reporting overall improvement in tinnitus severity (measured by asking "Has your tinnitus improved?") 6 weeks
with nortriptyline (titrated to maintain therapeutic blood levels for depression)
with placebo
Absolute numbers not reported

Reported as not significant
P value not reported
Not significant

Impact of tinnitus on quality of life

Tricyclic antidepressants (TCAs) compared with placebo Nortriptyline may be more effective at improving symptoms of depression at 6 weeks in people with tinnitus (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Depression

RCT
117 people; results are reported for the 92 people who completed the follow-up period
In review
Hamilton Depression Rating Scale score 6 weeks
11 with nortriptyline (titrated to maintain therapeutic blood levels for depression)
14 with placebo

P = 0.0001
Effect size not calculated nortriptyline

RCT
117 people; results are reported for the 92 people who completed the follow-up period
In review
Proportion of people reporting global satisfaction (measured by asking "Has the medication helped you in any way?") 6 weeks
33/49 (67%) with nortriptyline (titrated to maintain therapeutic blood levels for depression)
17/43 (40%) with placebo

P <0.01
Effect size not calculated nortriptyline

Resolution of tinnitus

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
37 people with no history of depression
In review
Adverse effects
with amitriptyline (50 mg/night for 1 week followed by 100 mg/night for 5 weeks)
with placebo

Statistical analysis between groups not reported

No data from the following reference on this outcome.

SSRIs versus placebo:

We found one systematic review (search date 2006; 1 RCT; 120 people) and one additional RCT comparing SSRIs versus placebo.

Improvement in tinnitus

SSRIs compared with placebo We don't know whether SSRIs are more effective at reducing the symptoms of tinnitus after 14 to 16 weeks (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus loudness

RCT
120 people
In review
Improvement in average pure tone
1.8 dB with paroxetine (10 mg/day, increased to maximum 50 mg/day for 100 days)
0.8 dB with placebo

P >0.05
Not significant

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Reduction in tinnitus loudness score (measured by visual analogue scale; scale of 0–100 mm; higher score denotes louder levels of tinnitus) 16 weeks
15.21 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
3.21 with placebo

P = 0.013
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Effect size not calculated sertraline
Overall symptoms of tinnitus

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in tinnitus severity questionnaire score (scale of 0–40; higher scores denote more severe tinnitus) 16 weeks
4.69 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
2.12 with placebo

P = 0.024
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Effect size not calculated sertraline

Impact of tinnitus on quality of life

SSRIs compared with placebo We don't know whether SSRIs are more effective at reducing annoyance, anxiety, and depression at 16 weeks in people with tinnitus (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Annoyance

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in tinnitus annoyance score (measured by visual analogue scale; scale of 0–100 mm; higher score denotes higher level of annoyance) 16 weeks
15.76 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
5.15 with placebo

Reported as not significant
P value not reported
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Not significant
Anxiety

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in clinician-rated anxiety score (measured by Hamilton Anxiety Rating Scale; scale of 0–56; higher score denotes higher level of anxiety) 16 weeks
8.51 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
4.09 with placebo

P = 0.037
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Effect size not calculated sertraline

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in participant-rated anxiety score (measured by Comprehensive Psychopathological Rating Scale [CPRS-S-A] for anxiety; scale of 0–54; higher score denotes higher level of anxiety) 16 weeks
4.38 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
0.73 with placebo

P = 0.013
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Effect size not calculated sertraline
Depression

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in participant-rated depression score (measured by CPRS-S-A for depression; scale of 0–60; higher score denotes higher level of depression) 16 weeks
5.93 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
0.05 with placebo

P = 0.002
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Effect size not calculated sertraline

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Change in clinician-rated depression score (measured by Hamilton Depression Rating Scale; scale 0–62; higher score denotes higher level of depression) 16 weeks
9.79 with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
5.87 with placebo

Reported as not significant
P value not reported
The RCT may have been underpowered to detect a clinically meaningful difference between groups
Not significant

Resolution of tinnitus

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
76 people with tinnitus considered to be at high risk of developing severe and disabling tinnitus Adverse effects 16 weeks
with sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks)
with placebo

The RCT may have been underpowered to detect a clinically meaningful difference between groups

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

Antidepressant drugs for tinnitus One RCT added comparing sertraline (25 mg/day for 1 week followed by 50 mg/day for 15 weeks) versus placebo. It found that sertraline improved tinnitus severity and loudness, clinician-rated anxiety, participant-rated anxiety, and participant-rated depression compared with placebo. However, it found no significant difference between sertraline and placebo in tinnitus annoyance and clinician-rated depression. Considering all evidence reported, potential benefits of antidepressant drugs in the treatment of tinnitus are unclear. Categorisation changed from Trade-off between benefits and harms to Unknown effectiveness.

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Benzodiazepines

Summary

We don't know whether benzodiazepines are effective in people with tinnitus, because very few studies have been carried out.

Long-term use of benzodiazepines can lead to dependence.

Benefits and harms

Benzodiazepines versus placebo:

We found one systematic review (search date 1995), which identified one RCT.

Improvement in tinnitus

Benzodiazepines compared with placebo Benzodiazepines may reduce the severity of tinnitus after 12 weeks (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus loudness

RCT
40 people
In review
Proportion of people with improvement in tinnitus (measured by tinnitus synthesiser and visual analogue scale [scale of 0–10; increasing score is associated with increasing loudness]) 12 weeks
13/17 (77%) with alprazolam (initially 0.5 mg/night)
1/19 (5%) with placebo

Significance not assessed
The RCT used dose adjustment of alprazolam but no dose adjustment of placebo, potentially biasing the results because of a difference in the attention given to people in the two groups

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
40 people
In review
Adverse effects
with alprazolam (initially 0.5 mg/night)
with placebo

The RCT used dose adjustment of alprazolam but no dose adjustment of placebo, potentially biasing the results because of a difference in the attention given to people in the two groups

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Cinnarizine

Summary

We don't know whether cinnarizine is effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Cinnarizine versus placebo:

We found one systematic review (search date 1998), which identified one RCT.

Improvement in tinnitus

Cinnarizine compared with placebo Cinnarizine may be no more effective at reducing the severity of tinnitus after 10 weeks (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms of tinnitus

RCT
30 people
In review
Proportion of people with subjective improvement of tinnitus (self-reported; severity measured on 5-point scale) 10 weeks
1/10 (10%) with cinnarizine (25 mg three times/day for 10 weeks)
1/20 (5%) with placebo

Reported as not significant
P value not reported
The RCT did not specify the follow-up period, and might have lacked power to detect a clinically important effect
Not significant

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Electromagnetic stimulation

Summary

We don't know whether electromagnetic stimulation is effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Electromagnetic stimulation versus placebo:

We found no systematic review, but found two small RCTs comparing electromagnetic stimulation versus placebo.

Improvement in tinnitus

Electromagnetic stimulation compared with placebo The effects of electromagnetic stimulation compared with placebo are unclear in people with tinnitus (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms of tinnitus

RCT
58 people Proportion of people who had improved tinnitus (assessed using a subjective response assessed by 4-point questionnaire — tinnitus worse, same, improved, or abolished) 1 week
14/31 (45%) with electromagnetic stimulation (15 minutes/day)
2/23 (9%) with placebo device

P = 0.0013
The RCT reported that 4/58 (7%) people withdrew from the trial, and that the analysis was not by intention to treat
Effect size not calculated electromagnetic stimulation

RCT
Crossover design
20 people Proportion of people who had improved tinnitus (tinnitus severity measured on a scale of 0–7)
2/20 (10%) with electrical suppression
3/20 (15%) with placebo device

Significance not assessed

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
58 people Adverse effects
with electromagnetic stimulation (15 minutes/day)
with placebo device

RCT
Crossover design
20 people Adverse effects
with electrical suppression
with placebo device

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Ginkgo biloba

Summary

We don't know whether ginkgo biloba is effective in people with tinnitus, because very few RCTs have been carried out.

Benefits and harms

Ginkgo biloba versus placebo:

We found one systematic review (search date 2006; 3 RCTs; 1143 adults with tinnitus) comparing ginkgo biloba versus placebo. The review did not perform a meta-analysis; the explicit reasoning was not specified, but the authors of the review noted that most RCTs were of poor quality. We have not reported two of the RCTs because of poor methods (pseudo-randomisation, unblinded assessors, selection of participants by previous positive response to ginkgo biloba), or high withdrawal rate.

Improvement in tinnitus

Ginkgo biloba compared with placebo Ginkgo biloba is no more effective at reducing the severity of tinnitus after 12 weeks (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms of tinnitus

RCT
66 people
In review
Mean change in Tinnitus Handicap Inventory score (scale of 1–100; increasing score is associated with increasing severity of handicap) 12 weeks
–4.7 with ginkgo biloba (120 mg/day)
–2.2 with placebo

P = 0.51
Not significant

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
66 people
In review
Proportion of people with diarrhoea 12 weeks
3% with ginkgo biloba (120 mg/day)
6% with placebo
Absolute numbers not reported

Significance not assessed

RCT
66 people
In review
Proportion of people with headache 12 weeks
3% with ginkgo biloba (120 mg/day)
3% with placebo
Absolute numbers not reported

Significance not assessed

Further information on studies

None.

Comment

None.

Substantive changes

Ginkgo biloba One systematic review updated (search date 2006), identifying the same RCTs as previously reported in this Clinical Evidence review. Categorisation unchanged (Unknown effectiveness).

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Hearing aids

Summary

We don't know whether hearing aids are effective in people with tinnitus, because very few RCTs have been carried out.

Benefits and harms

Hearing aids versus waiting list control:

We found no systematic reviews. We found one RCT comparing hearing aids versus a waiting list control in people who were having hearing aids fitted primarily for hearing loss, and who also had tinnitus.

Improvement in tinnitus

Hearing aids compared with waiting list control Hearing aids may be no more effective at reducing the severity of tinnitus after 6 weeks than being on a waiting list in people with hearing loss and tinnitus (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus intensity

RCT
39 people Perceived tinnitus intensity (measured on a 10 cm visual analogue scale) 6 weeks
with hearing aid (worn for 6 weeks)
with waiting list control
Absolute results not reported

Reported as not significant
P value not reported
Not significant

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Hypnosis

Summary

We don't know whether hypnosis is effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Hypnosis versus counselling:

We found one systematic review (search date 1995) and one additional RCT. The review found no RCTs that met its inclusion criteria.

Improvement in tinnitus

Hypnosis compared with counselling Self-hypnosis training may be no more effective than a single counselling session at reducing the severity of tinnitus after 3 months (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms (other than loudness) of tinnitus

RCT
92 people pre-selected to be suggestible to hypnosis Proportion of people who had improved symptom severity scores 3 months
24/44 (55%) with hypnosis (three sessions teaching self-hypnosis)
23/42 (55%) with counselling (single session)

Reported as not significant
P value not reported
Not significant

RCT
92 people pre-selected to be suggestible to hypnosis Proportion of people reporting worsened tinnitus 3 months
14/44 (32%) with hypnosis (three sessions teaching self-hypnosis)
11/42 (26%) with counselling (single session)

Reported as not significant
P value not reported
Not significant

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Psychotherapy

Summary

CBT may be ineffective at reducing tinnitus loudness, but it may improve quality of life in people with tinnitus.

Benefits and harms

CBT versus placebo:

We found two systematic reviews. The first review (search date 2006; 6 RCTs; 285 people) assessed CBT in patients with tinnitus. The second review (search date 1998; 8 RCTs; 269 people) assessed different psychotherapeutic approaches (CBT, relaxation therapy, education/information, biofeedback).

Improvement in tinnitus

CBT compared with placebo CBT may be no more effective at reducing the severity of tinnitus (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Tinnitus loudness

Systematic review
171 people
4 RCTs in this analysis
Tinnitus loudness
with CBT
with placebo
Absolute results not reported

SMD +0.06
95% CI –0.25 to +0.37
Not significant

Systematic review
269 people
8 RCTs in this analysis
Reduction in subjective tinnitus loudness 3 months or more post treatment
with CBT (combination of different psychotherapeutic approaches)
with placebo
Absolute results not reported

SMD 0.68
95% CI 0.62 to 0.74
The review had important flaws in its methods, compromising its validity (see further information on studies for more details)
Effect size not calculated CBT

Impact of tinnitus on quality of life

CBT compared with placebo CBT may be more effective at improving quality-of-life and tinnitus annoyance scores, but we don't know whether it is more effective at improving symptoms of depression (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Depression

Systematic review
152 people
4 RCTs in this analysis
Symptoms of depression
with CBT
with placebo
Absolute results not reported

SMD +0.29
95% CI –0.04 to +0.63
Not significant
Quality of life

Systematic review
126 people
3 RCTs in this analysis
Quality-of-life scores
with CBT
with placebo
Absolute results not reported

SMD 0.7
95% CI 0.33 to 1.08
Effect size not calculated CBT
Tinnitus annoyance

Systematic review
269 people
8 RCTs in this analysis
Reduction in subjective tinnitus annoyance 3 months or more post treatment
with CBT (combination of different psychotherapeutic approaches)
with placebo
Absolute results not reported

SMD 0.83
95% CI 0.82 to 0.84
The review had important flaws in its methods, compromising its validity (see further information on studies for more details)
Effect size not calculated CBT

Resolution of tinnitus

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

Systematic review
Adverse effects
with CBT
with placebo

No data from the following reference on this outcome.

Further information on studies

The review pooled study results across arms of trials, losing the benefits of randomisation and increasing the risk of bias. In addition, pre-treatment to post-treatment effect sizes do not allow comparison of psychotherapy with no treatment or any other treatment. The review also did not report which interventions were used as controls in the RCTs.

Comment

Despite many studies on psychotherapeutic measures to treat tinnitus, the evidence for benefit remains limited. Many of the RCTs suffer from less reliable methods, high withdrawal rates, and pooled or surrogate outcome measures.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Tinnitus-masking devices

Summary

We don't know whether tinnitus-masking devices are effective in people with tinnitus, because very few studies have been carried out.

Benefits and harms

Tinnitus-masking devices versus placebo:

We found one systematic review (search date 1998; 2 RCTs). One RCT was of insufficient quality to include in this review: the RCT had a high withdrawal rate (67%) and was unblinded.

Improvement in tinnitus

Tinnitus-masking devices compared with placebo Tinnitus-masking devices may be no more effective at reducing the severity of tinnitus (very low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms (other than loudness) of tinnitus

RCT
Crossover design
21 people
In review
Proportion of people with a significant improvement from baseline in intensity of tinnitus symptoms (assessed using tinnitus intensity rating [scale of 0–10])
7/17 (41%) with tinnitus masking device
5/17 (29%) with placebo

Significance not assessed
Reported results were post-crossover; post-crossover results are difficult to interpret because of the possibility of a persistence of treatment effect after crossover
Data were omitted for 4/21 (19%) people for inadequate use of the tinnitus rating scale

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
Crossover design
21 people
In review
Adverse effects
with tinnitus masking device
with placebo

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Tinnitus retraining therapy

Summary

We don't know whether tinnitus retraining therapy is effective in people with tinnitus.

We found no clinically important results from RCTs about the effects of tinnitus retraining therapy in people with chronic tinnitus.

Benefits and harms

Tinnitus retraining therapy:

We found no systematic review or RCTs of tinnitus retraining therapy in people with chronic tinnitus.

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence

BMJ Clin Evid. 2009 Nov 12;2009:0506.

Carbamazepine

Summary

Carbamazepine may be no more effective than placebo at improving symptoms of tinnitus, and is associated with adverse effects such as dizziness, nausea, and headache.

Carbamazepine can cause dizziness, nausea, and headaches.

Benefits and harms

Carbamazepine versus placebo:

We found one systematic review (search date 1998), which identified one RCT.

Improvement in tinnitus

Carbamazepine compared with placebo Carbamazepine may be no more effective at reducing the severity of tinnitus after 30 days (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Overall symptoms of tinnitus

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with an improvement in tinnitus severity (assessed by people stating that "tinnitus was no longer annoying") 30 days
2/24 (8%) with carbamazepine (150 mg three times/day for 30 days)
3/24 (13%) with placebo

Significance not assessed

Resolution of tinnitus

No data from the following reference on this outcome.

Impact of tinnitus on quality of life

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with dizziness 30 days
8/24 (33%) with carbamazepine (150 mg three times/day for 30 days)
0/24 (0%) with placebo

Significance not assessed

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with nausea 30 days
8/24 (33%) with carbamazepine (150 mg three times/day for 30 days)
0/24 (0%) with placebo

Significance not assessed

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with headache 30 days
4/24 (17%) with carbamazepine (150 mg three times/day for 30 days)
1/24 (4%) with placebo

Significance not assessed

RCT
48 people with "annoying tinnitus"
In review
Proportion of people reporting tiredness 30 days
2/24 (8%) with carbamazepine (150 mg three times/day for 30 days)
0/24 (0%) with placebo

Significance not assessed

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with vomiting 30 days
2/24 (8%) with carbamazepine (150 mg three times/day for 30 days)
0/24 (0%) with placebo

Significance not assessed

RCT
48 people with "annoying tinnitus"
In review
Proportion of people with diarrhoea 30 days
1/24 (4%) with carbamazepine (150 mg three times/day for 30 days)
0/24 (0%) with placebo

Significance not assessed

Further information on studies

None.

Comment

None.

Substantive changes

No new evidence


Articles from BMJ Clinical Evidence are provided here courtesy of BMJ Publishing Group

RESOURCES